Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Lymphoma

Free Subscription Articles published in Cancer Retrieve available abstracts of 43 articles: HTML format

Single Articles

August 2026
1. GIBRAN-NUNES F, Pecego H, Santos J, Nunes Y, et al
   Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.
   Cancer. 2026;132:e70543.
   PubMed     Abstract available
   
   
   July 2026
2. OLIVIERI J, Gattei V, Dal Maso L
   Bendamustine in indolent lymphoma: Letting the dust settle down.
   Cancer. 2026;132:e70527.
   PubMed    
   
   
   
3. THARMASEELAN H, Jablonski J, Buhnen I, Fuchs M, et al
   Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.
   Cancer. 2026;132:e70532.
   PubMed     Abstract available
   
   
   
4. SUZUKI K, Miyazaki K, Yamaguchi M
   Reply to "Pulmonary mucosa-associated lymphoid tissue lymphoma: Is gastric involvement underdiagnosed?".
   Cancer. 2026;132:e70535.
   PubMed    
   
   
   
5. COUDERC LJ, Catherinot E
   Pulmonary mucosa-associated lymphoid tissue lymphoma: Is gastric involvement underdiagnosed?
   Cancer. 2026;132:e70534.
   PubMed    
   
   
   
6. LAWRENCE L
   Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.
   Cancer. 2026;132:e70455.
   PubMed    
   
   
   April 2026
7. DANILOV AV, Coombs CC, Phillips T, Allan JN, et al
   Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
   Cancer. 2026;132:e70389.
   PubMed     Abstract available
   
   
   
8. SUZUKI K, Miyazaki K, Asano N, Takahashi H, et al
   Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.
   Cancer. 2026;132:e70390.
   PubMed     Abstract available
   
   
   
9. AKKAD N, Chen M, Nguyen S, Romero A, et al
   Assessing patient perspectives on enrollment in lymphoma clinical trials.
   Cancer. 2026;132:e70377.
   PubMed     Abstract available
   
   
   
10. GAO Y, Jiang M, Zhang X, Liu L, et al
    Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment-naive peripheral T-cell lymphoma: A multicenter, open-label, single-arm, phase 1b trial.
    Cancer. 2026;132:e70360.
    PubMed     Abstract available
    
    
    March 2026
11. DAVIES GA, Prica A, Ante Z, Liu N, et al
    Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab.
    Cancer. 2026;132:e70327.
    PubMed     Abstract available
    
    
    February 2026
12. MANTZ L, Johnson PC, Lei M, Newcomb RA, et al
    Exploratory association of muscle and adipose tissue indices with clinical outcomes in aggressive lymphomas.
    Cancer. 2026;132:e70313.
    PubMed     Abstract available
    
    
    
13. TANG L, Cai D, Yan X, Mo W, et al
    Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.
    Cancer. 2026;132:e70317.
    PubMed     Abstract available
    
    
    January 2026
14. YILMAZ U, Dal MS, Ulas T, Atesoglu EB, et al
    Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world
    Cancer. 2026;132:e70248.
    PubMed     Abstract available
    
    
    
15. KONOPLEVA M, Pemmaraju N, Sweet KL, Stein AS, et al
    Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
    Cancer. 2026;132:e70243.
    PubMed     Abstract available
    
    
    
16. ZHAO W, Li L, Fu X, Chang Y, et al
    A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.
    Cancer. 2026;132:e70247.
    PubMed     Abstract available
    
    
    December 2025
17. SHI W, Ren Y, Liu S, Liu Y, et al
    Clinical characteristics and survival outcomes of thymic mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients.
    Cancer. 2025;131:e70183.
    PubMed     Abstract available
    
    
    September 2025
18. TAN S, He H, Ni J, Guo Y, et al
    Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary ce
    Cancer. 2025;131:e70083.
    PubMed     Abstract available
    
    
    
19. NIERENGARTEN MB
    Safety and promising efficacy with enhanced CAR T-cell therapy for lymphoma.
    Cancer. 2025;131:e70035.
    PubMed    
    
    
    June 2025
20. 
    Correction to "Surveillance imaging during first remission in follicular lymphoma does not impact overall survival".
    Cancer. 2025;131:e35934.
    PubMed    
    
    
    
21. NIERENGARTEN MB
    Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma.
    Cancer. 2025;131:e35899.
    PubMed    
    
    
    
22. 
    Correction to "Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study".
    Cancer. 2025;131:e35933.
    PubMed    
    
    
    March 2025
23. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    PubMed     Abstract available
    
    
    
24. JIMENEZ MUNARRIZ BE, Khan S, Li Y, Ghazali N, et al
    Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment.
    Cancer. 2025;131 Suppl 1:e35786.
    PubMed     Abstract available
    
    
    January 2025
25. YIN X, He Q, Liu D, Xie L, et al
    Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.
    Cancer. 2025;131:e35697.
    PubMed     Abstract available
    
    
    
26. GAO Y, Huang Y, Zhang Q, Yang H, et al
    Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
    Cancer. 2025;131:e35672.
    PubMed     Abstract available
    
    
    November 2024
27. HANZLIK E, Sabin ND, Yoshida T, Delaney A, et al
    Sexual dysfunction among long-term survivors of Hodgkin lymphoma.
    Cancer. 2024 Nov 7. doi: 10.1002/cncr.35637.
    PubMed     Abstract available
    
    
    
28. LI Z, Li X, Li S, Tao R, et al
    Preclinical evaluation and phase 1 study of the PI3Kalpha/delta inhibitor TQ-B3525 in Chinese patients with advanced cancers.
    Cancer. 2024;130:3686-3698.
    PubMed     Abstract available
    
    
    October 2024
29. NIERENGARTEN MB
    Multitargeted therapy is safe and leads to durable remission of DLBCL.
    Cancer. 2024;130:3238.
    PubMed    
    
    
    August 2024
30. ZENG C, Wei Z, Huang J, Zhu J, et al
    Effect of body mass index on the prognosis of children and adolescents with high-grade mature B-cell non-Hodgkin lymphoma.
    Cancer. 2024 Aug 22. doi: 10.1002/cncr.35536.
    PubMed     Abstract available
    
    
    June 2024
31. HSU YT, Wu SJ, Kao HW, Hsiao SY, et al
    Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Cancer. 2024;130:1972-1981.
    PubMed     Abstract available
    
    
    May 2024
32. LI ZH, Zhang MY, Federico M, Civallero M, et al
    Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation.
    Cancer. 2024 May 29. doi: 10.1002/cncr.35378.
    PubMed     Abstract available
    
    
    April 2024
33. NIERENGARTEN MB
    Golidocitinib favorable for relapsed/refractory T-cell lymphoma.
    Cancer. 2024;130:1191-1192.
    PubMed    
    
    
    
34. LI A, Yi H, Deng S, Ruan M, et al
    The genetic landscape of histologically transformed marginal zone lymphomas.
    Cancer. 2024;130:1246-1256.
    PubMed     Abstract available
    
    
    
35. GIRI S, Harmon C, Landier W, Chen Y, et al
    Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35298.
    PubMed     Abstract available
    
    
    February 2024
36. WU S, Rhee JW, Iukuridze A, Bosworth A, et al
    Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35252.
    PubMed     Abstract available
    
    
    
37. TZANKOV A, Tatarczuch M
    Time to Be Launched 1 auXiliary Risk strat1fier in marginal zone lymphoma transformation: TBL1XR1.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35246.
    PubMed    
    
    
    January 2024
38. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    PubMed     Abstract available
    
    
    December 2023
39. DAI L, Chen H, Tan Q, Wang Y, et al
    Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
    Cancer. 2023 Dec 22. doi: 10.1002/cncr.35158.
    PubMed     Abstract available
    
    
    
40. CHU Y, Liu Y, Yu Z, Zhan L, et al
    Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
    Cancer. 2023 Dec 2. doi: 10.1002/cncr.35137.
    PubMed     Abstract available
    
    
    November 2023
41. GORDON MJ, Feng L, Strati P, Lee HJ, et al
    Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35114.
    PubMed     Abstract available
    
    
    
42. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    PubMed    
    
    
    
43. WADHWA A, Lim S, Dai C, Daniels G, et al
    Assessment of longitudinal changes in body composition of children with lymphoma and rhabdomyosarcoma.
    Cancer. 2023;129:3457-3465.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum